OBJECTIVE: To probe into the clinical efficacy of acupoint application combined with Xuefuzhuyu decoction in the treatment of patients with primary dysmenorrhea of Qi-stagnation and blood-stasis syndrome. METHODS: Totally 102 patients with primary dysmenorrhea admitted into the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine from Jun. 2019 to Dec. 2020 were extracted to be divided into the control group and the study group via the random number table

with 51 cases in each group. The control group was given Xuefuzhuyu decoction

while the study group received acupoint application combined with Xuefuzhuyu decoction. After treatment

the clinical efficacy of two groups were evaluated

and the occurrence of adverse drug reactions during treatment was observed. The visual analogue scale（VAS）

traditional Chinese medicine symptom score and levels of serum prostaglandin E2（PGE2）

prostaglandin F2α（PGF2α）

tumor necrosis factor α（TNF-α）

interleukin-6（IL-6） and high-sensitivity C-reactive protein（hs-CRP） of two groups were compared before and after treatment. RESULTS: The total effective rate of the study group was 96.08%（49/51）

significantly higher than 80.39%（41/51） of the control group

the difference was statistically significant（P<0.05）. After treatment

the VAS score and traditional Chinese medicine symptom score of the study group were significantly lower than those of the control group

the level of serum PGE2 was significantly higher than that of the control group

and the levels of serum PGF2α

TNF-a

IL-6 and hs-CRP were significantly lower than those of the control group

with statistically significant differences（P<0.05）. During the treatment

no severe adverse drug reactions occurred in both groups. CONCLUSIONS: Acupoint application combined with Xuefuzhuyu decoction in the treatment of patients with primary dysmenorrhea can significantly improve the curative effect

improve patients’ symptoms

relieve the pain

inhibit the inflammatory reaction

and regulate the level of serum prostate metabolites with higher safety.